QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.108.022822v1 36/11/2316    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Agostino, J. Articles by Ding, X. Search for Related Content PubMed PubMed Citation Articles by D'Agostino, J. Articles by Ding, X.

Characterization of CYP2A13^*2, a Variant Cytochrome P450 Allele Previously Found to Be Associated with Decreased Incidences of Lung Adenocarcinoma in Smokers

Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Albany, New York (J.D., X.Z., H.W., G.L., S.W., Q.-Y.Z., X.D.); Department of Epidemiology, Shanxi Medical University, Taiyuan, China (S.W.); and Department of Thoracic Surgery, Shanxi Tumor Hospital, Taiyuan, China (F.L.)

CYP2A13, a human cytochrome P450 enzyme expressed mainly in the respiratory tract, is believed to play an important role in the initiation of smoking-induced lung cancer. CYP2A13.1 has high efficiency in the metabolic activation of a major tobacco-specific carcinogenic nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). CYP2A13^*2, a variant allele, was previously found to be associated with decreased incidence of lung adenocarcinoma in smokers. The aim of the present study was to determine whether the CYP2A13.2 protein has decreased enzyme activity and/or expression levels in the lung, compared with CYP2A13.1. CYP2A13.2 has two sequence variations from CYP2A13.1: R25Q and R257C. We compared the activities of heterologously expressed CYP2A13.1 and CYP2A13.2 toward several known CYP2A13.1 substrates: NNK, N-nitrosomethylphenylamine, N,N-dimethylaniline, 2'-methoxyacetophenone, and hexamethylphosphoramide. Our results indicated that CYP2A13.2 was 20 to 40% less active than CYP2A13.1 with the substrates tested. We also determined the levels of the CYP2A13^*2 mRNA, relative to the level of the CYP2A13^*1 mRNA, in the lung tissue from ^*1/^*2 heterozygotes. We found that the CYP2A13^*2 allele was associated with a level of allelic expression 40% lower than that of the CYP2A13^*1 allele. Sequence analysis of the promoter region of the CYP2A13^*2 allele identified a 26-nucleotide deletion. Functional analysis of a 2-kilobase pair CYP2A13-luciferase promoter construct indicated that the 26-nucleotide deletion causes decreases in CYP2A13 promoter activity in the A549 human lung cell line. These findings suggest that the reported association of the CYP2A13^*2 allele with decreased incidences of lung adenocarcinoma in smokers can be at least partly explained by a decrease in CYP2A13 function.

This article has been cited by other articles:

				J. D'Agostino, X. Zhuo, M. Shadid, D. G. Morgan, X. Zhang, W. G. Humphreys, Y.-Z. Shu, G. S. Yost, and X. Ding The Pneumotoxin 3-Methylindole Is a Substrate and a Mechanism-Based Inactivator of CYP2A13, a Human Cytochrome P450 Enzyme Preferentially Expressed in the Respiratory Tract Drug Metab. Dispos., October 1, 2009; 37(10): 2018 - 2027. [Abstract] [Full Text] [PDF]

				L.-L. Wang, Y. Li, and S.-F. Zhou A Bioinformatics Approach for the Phenotype Prediction of Nonsynonymous Single Nucleotide Polymorphisms in Human Cytochromes P450 Drug Metab. Dispos., May 1, 2009; 37(5): 977 - 991. [Abstract] [Full Text] [PDF]